A Phase 2 dose ranging study of ATI-50001 for the oral treatment of alopecia totalis and alopecia universalis
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs ATI 50001 (Primary)
- Indications Alopecia areata
- Focus Adverse reactions
- 15 Mar 2017 According to an Aclaris Therapeutics media release, the company is planning to initiate this trial in the second half of 2017.
- 16 Nov 2016 New trial record
- 03 Nov 2016 According to an Aclaris Therapeutics media release, the company is planning to commence this trial in the first half of 2017.